Efficacy and Safety of Upadacitinib vs Dupilumab in Adults and ...

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With ...

Upadacitinib provides superior and more rapid skin clearance and itch relief with tolerable safety compared with dupilumab in patients with moderate-to-severe ...

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With ...

During 16 weeks of treatment, upadacitinib demonstrated superior efficacy vs dupilumab in patients with moderate-to-severe AD, with no new safety signals.

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With ...

Upadacitinib achieved higher levels of skin clearance and itch relief with a more rapid onset of action vs dupilumab. Upadacitinib is an ...

734 - Efficacy and safety of upadacitinib vs dupliumab in adults and ...

Proportions of patients with any treatment-emergent adverse event were higher for upadacitinib (65.3%) than dupilumab (52.7%). Severe adverse ...

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults and ...

Level Up is a phase 3b/4 global, randomized, open-label, efficacy assessor blinded study evaluating UPA vs DUPI in adolescents and adults with moderate-to- ...

Efficacy and safety of switching from dupilumab to upadacitinib ...

Upadacitinib was well-tolerated and maintained high levels of skin clearance and itch improvement through 40 weeks in patients with moderate-to- ...

"Efficacy and safety of upadacitinib vs dupliumab in adults and ...

Efficacy and safety of upadacitinib vs dupliumab in adults and adolescents with moderate-to-severe atopic dermatitis: results of an open-label, ...

New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority ...

Upadacitinib also showed superiority versus dupilumab for all ranked secondary endpoints, including the rapid onset of achieving near complete ...

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults with ...

Conclusions and Relevance: During 16 weeks of treatment, upadacitinib demonstrated superior efficacy vs dupilumab in patients with moderate-to-severe AD, with ...

Efficacy and safety of switching from dupilumab to upadacitinib ...

A few case studies have reported maintained or improved skin clearance and itch reduction with upadacitinib treatment among patients who discontinued dupilumab ...

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults and ...

RESULTS. Superior efficacy in achieving simultaneous EASI 90 and WP-NRS 0/1 response at Week 16 was demonstrated with UPA vs DUPI (19.9% vs 8.9% ...

Efficacy of Upadacitinib and Dupilumab on Achieving Stringent and ...

Upadacitinib and dupilumab are two treatment options for atopic dermatitis. Upadacitinib is an oral, small-molecule Janus kinase inhibitor that ...

Level Up: Efficacy and Safety of Upadacitinib vs Dupilumab in Adults ...

Raj Chovatiya, MD, PhD, MSCI; and Christopher Bunick, MD, PhD; analyze clinical trial data, compare treatment efficacies of upadacitinib and dupilumab, ...

Efficacy and safety of abrocitinib and upadacitinib versus dupilumab ...

Compared with dupilumab, a larger proportion of patients treated with abrocitinib/upadacitinib achieved early itch relief at 2 weeks. Better ...

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults and ...

Treatment with upadacitinib was superior to treatment with dupilumab in patients with moderate to severe atopic dermatitis when evaluated based ...

Efficacy and safety of abrocitinib versus dupilumab in adults with ...

Abrocitinib 200 mg per day was more efficacious than dupilumab in adults with moderate-to-severe atopic dermatitis on background topical therapy ...

Efficacy and safety of switching from dupilumab to upadacitinib ...

Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA ...

Efficacy and Safety of Upadacitinib in Patients With Moderate to ...

Meaning This follow-up analysis of 2 randomized clinical trials found that continuous upadacitinib treatment showed a favorable longer-term ...

Efficacy and safety of abrocitinib versus dupilumab in adults with ...

This was the Heads Up phase 3 trial (NCT03738397 ), which showed the greater efficacy of upadacitinib 30 mg per day versus dupilumab 300 mg ...

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults with ...

Pharmacology, Toxicology and Pharmaceutical Science · Randomized Clinical Trial · Dupilumab · Atopic Dermatitis · Upadacitinib · Pruritus · Adverse Event · Infection ...